12A-1100819
US provisional application
Abstract
Sleep disruption gradually becomes a serious issue that impacts Alzheimer’s disease (AD)patients. Sleep disorders are also a risk factor that involves mild to moderate forms of AD. Moreover, the typical pathological markers of AD have been suggested that correlated
with the decrease of sleep amount. Adenosine has been reported as a sleep-promoting substance that can through the A1R and A2AR to stimulate sleep. ENT1 (Equilibrative nucleoside transporter 1) is an integral membrane protein and serves an important role in
the transportation of adenosine. Inhibition of ENT1 leads to extracellular adenosine augmentation has been reported. In this invention, we found a new compound can be used to treat sleep disorders, especially those induced by AD and other degenerative disease as well.
- Oral active adenosine analogue that can pass the blood-brain-barrier
- Modulate adenosine transporter and A2A receptors, which facilitate sleep.
Drug development
Yijuang Chern, Fang-Chia Chang, Jim-Min Fang
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

A compound for the treatment of sleep disruptions